Pharma & Biotech
-
Delco the Statewide Center for Litigation of Opioid Cases, but Some Plaintiffs Want Out
Ever since Delaware County became the first county in Pennsylvania to sue opioid manufacturers 18 months ago, it has become the statewide center for litigation against those manufacturers and the distributors, writes Catherine Dunn for the Philadelphia Inquirer. According to the Inquirer, “Delco’s attorneys say coordinating the cases in one place – and putting them…
-
Here’s a Look at the Numbers as State’s Medical Marijuana Program Celebrates Successful First Year
Pennsylvania’s medical marijuana program celebrated a successful first year after thousands of patients generated millions of dollars in sales and provided substantial tax revenue, writes Sam Ruland for the York Daily Record. According to the Pennsylvania Department of Health, more than 116,000 Pennsylvanians are already registered as patients. Of these, 83,000 have received their identification…
-
Radnor’s Adapt Pharma Touts Awareness, Access to Its Antidote for Opioid Overdoses
Adapt Pharma of Radnor is trying to make Narcan, a nasal-spray antidote to an opioid overdose, as widely available as a flu shot, writes Erin Arvedlund for The Philadelphia Inquirer. Every day, an estimated 115 people die from opioid overdoses. About half of that number dies from prescription drugs. The other half dies from illegal…
-
Radnor Startup Develops Therapies for Rare Conditions with No Current Treatment
Radnor startup Palvella Therapeutics is tackling rare conditions that currently have no approved treatment, writes John George for the Philadelphia Business Journal. The company was founded by Wes Kaupinen three years ago. Before that, he helped launch life sciences companies as a venture capitalist. Palvella means “to serve” in Finnish, a tribute to Kaupinen’s ancestry.…
-
San Francisco-Based Syapse Expands Presence in Radnor
Syapse, a medical technology company from San Francisco that specializes in precision oncology, is expanding its Radnor presence, writes John George for the Philadelphia Business Journal. The company aims to double its workforce in the area from 15 to 30 this year. “Our goal is to make precision medicine available to every cancer patient who…
-
Radnor-Based VWR Foundation to Donate $50,000 to St. Jude Children’s Hospital
The VWR Foundation celebrated the VWR salesforce at the company’s 2018 Americas Sales Conference, and the foundation, which is dedicated to giving back to the science community, will be donating $50,000 to St. Jude Children’s Research Hospital. VWR, acquired by Avantor in 2017 as a wholly-owned subsidiary and leading global provider of product and service…
-
Narcan Nasal Spray from Radnor’s Adapt Pharma a Lifesaver for Families of Addicts
Narcan Nasal Spray from Radnor’s Adapt Pharma is now more easily available to anybody who might need it, making it a true lifesaver for families of opioid addicts, writes Alexandra Rockey Fleming for The Washington Post. When administered within the critical first minutes of a potentially deadly overdose, or even up to an hour later…
-
New Ad Campaign Promotes Region as ‘Cellicon Valley’
The Philadelphia region will be promoted as “Cellicon Valley” in an ad blitz at this week’s J.P. Morgan Healthcare Investor Conference in San Francisco, writes John George for the Philadelphia Business Journal. The annual gathering is the nation’s largest event on life sciences and healthcare. More than 8,000 attendees visit the conference, including investors, biotechnology,…
-
DELCO Careers – Adapt Pharma
Manufacturer of Narcan, a prescription medicine used to treat an opioid overdose, Radnor-based Adapt Pharma has the following Delaware County Career position posted: Customer Service and Operations Specialist Adapt seeks a Customer Service and Operations Specialist to manage day to day customer needs and facilitate necessary support to ensure access to Adapt products and work…
-
Radnor-Based Biotech Company Raises $800,000 in Funding
Radnor’s Opsidio, which is working on developing monoclonal antibodies for treatment of fibrotic diseases, has raised $800,000 through a debt financing deal, writes John George for the Philadelphia Business Journal. Opsidio’s technology targets fibrosis, the sometimes debilitating or even fatal formation of excess fibrous connective tissue in an organ or tissue during a reparative or…
-
Radnor’s Marinus Pharmaceuticals Aims to Generate $35 Million from Public Stock Offering
Radnor’s Marinus Pharmaceuticals is looking to raise $35 million from its public offering of 9.3 million shares of its common stock priced at $3.75 per share, writes John George for the Philadelphia Business Journal. The biopharmaceutical company has also granted the underwriter the option to purchase an additional 1.4 million shares of common stock within…
-
Biopharmaceutical Research Pumps Staggering Amount of Money into State’s Economy
Biopharmaceutical research is continuing to generate big business in Pennsylvania and helping boost the state’s economy, writes John George for the Philadelphia Business Journal. According to a report by the Pharmaceutical Research and Manufacturers of America, pharmaceutical research companies generate $68.9 billion annually, from both direct and indirect economic activity. The study, conducted by TEConomy…
-
Radnor’s L.E.A.F. Pharmaceuticals Establishes Subsidiary in Rwanda
Radnor’s L.E.A.F. Pharmaceuticals – a global pharmaceutical company with a mission to discover, develop, and commercialize innovative and safe therapies for cancer – has announced the establishment of L.E.A.F. Rwanda Ltd., a biotechnology company headquartered in Kigali, Rwanda. L.E.A.F. Rwanda, a fully owned subsidiary of L.E.A.F. Pharmaceuticals, will focus on establishing Rwanda as a hub…
-
Radnor’s Complexa Raises $62 Million in Funding
Complexa, a biopharmaceutical company in Radnor, has raised $62 million from a Series C financing round that was led by New Enterprise Associates and Pfizer Venture Investments, writes Alison Burdo for the Philadelphia Business Journal. “This financing enables Complexa to advance CXA-10, the first drug candidate from our novel nitrated fatty acid platform, into Phase…
-
Behind the Scenes of the $6.4 Billion Proposed Sale of Radnor’s VWR
A big new experiment at VWR in Radnor would bring in a new owner for the supplier of lab products. The company is mulling a proposed $6.4 billion sale to Avantor, according to a Philadelphia Business Journal report by John George. VWR and Avantor share a years-long distribution and supply relationship, but it wasn’t until…
-
Radnor’s VWR Donates $35,000 to Charity in Toronto
For Radnor’s VWR, business is doing well north of the border, and as a result, one of Canada’s most noteworthy charities is now the beneficiary. Through its VWR Collection program, the world’s leading independent provider of products and services to laboratory and production facilities donated $35,000 to Toronto’s SickKids Foundation. The VWR Collection program annually…
-
Chemical Products Manufacturer from Lehigh Valley Acquires Radnor’s VWR for $6.4 Billion
Avantor, a chemical products manufacturer in Center Valley, has agreed to purchase Radnor’s VWR for $6.4 billion, writes John George for the Philadelphia Business Journal. With more than 10,000 employees around the globe, VWR generated sales of $4.5 billion last year. The company distributes close to 1.2 million products to approximately 250,000 companies and educational…
-
Rosemont’s Duchesnay USA Partners with Actress to Raise Awareness of Morning Sickness
Rosemont’s Duchesnay USA has partnered with award-winning singer and actress Jana Kramer to raise awareness of Diclegis, the company’s morning sickness treatment. One of country music’s brightest stars, Kramer is also known for her role as Alex Dupre on the One Tree Hill television series. Last year, Kramer spent several months touring and promoting her…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
